Study
) Phase II trial is an investigator-sponsored, randomized Phase II clinical trial that will recruit patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma across 10 clinical sites in Germany. The trial will evaluate the addition of UV1 to a standard of care treatment with PD-1 checkpoint inhibitor pembrolizumab as compared to pembrolizumab monotherapy. A total of 75 patients indicated for treatment with pembrolizumab will be enrolled in the FOCUS study, randomized 2-to-1 so that 50 patients will receive UV1 and pembrolizumab and 25 patients will receive pembrolizumab alone. The primary endpoint of the study is the progression-free survival rate at 6 months, and planned readout of topline results is expected in 2023. The FOCUS Phase II trial is partially supported through an innovation grant of up to NOK 16 million from the Norwegian Research Council and will not require Ultimovacs to secure additional financing at this stage.
A comprehensive review of early-onset colorectal SEER data is the first to specifically assess adenocarcinomas medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
URL goes live when the embargo lifts
In a comprehensive review of SEER (Surveillance, Epidemiology, and End Results) 18 data researchers analyzed histologic colorectal subtypes independently and found that some lesions categorized as colorectal cancer may potentially be lower-risk tumors. The findings are published in
Annals of Internal Medicine.
Data indicate that adenocarcinomas are increasing in most early-onset subgroups, but that carcinoids, a distinct type of tumor, are increasing at a faster rate, at least in part because of increased detection and case capture by cancer registries.
Researchers from Tulane University Medical Center reviewed SEER 18 data from 2000 to 2016 for 119,624 patients with colorectal cancer to assess early-onset colorectal cancer incident rates and changes in incident rates over time, stratified by histologic subtype (primarily adenocarcinoma and carcinoid tumors). Adenocarcinoma is key to analyze because it is a target for prevention through scre
Ultimovacs ASA: Ultimovacs Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share:
International medical imaging IT and cybersecurity company Sectra
(STO: SECT B) has secured an enterprise imaging contract from the South-Eastern Norway Regional Health Authority. The contract comprises a radiology module and a region-wide multimedia solution (VNA) to store medical images and multimedia across all medical specialties. The platform will increase efficiency and collaboration across the region and beyond, translating into improved healthcare for its patients. We are pleased that we have the agreement in place. The regional solution is strongly needed and will improve the quality of patient care. Clinicians will have faster and easier access to patient information, thus can shorten lead times, comments Cathrine M. Lofthus, CEO, South-Eastern Norway Regional Health Authority (helse-sorost.no).